The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study.
2型糖尿病患者使用SGLT2抑制劑尿路感染的發生率和危險因素:一項真實世界觀察性研究。
Medicines (Basel) 2022-12-27
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
第二型糖尿病患者中不同鈉葡萄糖轉運蛋白2抑制劑的比較安全性:對隨機對照試驗的系統性回顧和網絡荟萃分析。
Front Endocrinol (Lausanne) 2023-09-15
Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
第二型糖尿病患者中不同建議劑量的鈉葡萄糖共同轉運蛋白2抑制劑的比較安全性:一項隨機臨床試驗的系統性回顧和網絡荟萃分析。
Front Endocrinol (Lausanne) 2024-02-29
Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database.
使用索引資料庫進行的回顧性世代研究:與鈉葡萄糖共同轉運蛋白-2抑制劑相關的泌尿生殖系細菌感染風險。
Diabetes Ther 2024-07-03
Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial.
接受 SGLT2 抑制劑治療的第二型糖尿病患者中的泌尿生殖感染和尿路感染:來自具有里程碑意義的隨機臨床試驗的系統文獻回顧證據。
Drug Res (Stuttg) 2024-07-11
Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.
美國退伍軍人中患有慢性腎臟疾病與無慢性腎臟疾病者使用 SGLT2 抑制劑、DPP-4 抑制劑和 GLP-1 受體激動劑的安全性:一項基於人口的研究。
Lancet Reg Health Am 2024-07-12